

March 07, 2023

Podcast - a new audio formulation for our PD(L)anner



[Jacob Plieth](#)

Evaluate Vantage [recently published](#) the latest in a series of reports on the PD-(L)1 inhibitor space, covering all the major clinical, regulatory and commercial milestones since last September, and outlining key upcoming catalysts. To accompany this edition we've recorded a podcast in which I was delighted to be joined by Bertrand Delsuc, publisher of [Biotech Radar](#) and an [essential follow on Biotwitter](#). We discuss numerous upcoming Tigit catalysts, look at some of the latest developments with bispecifics, and ask whether AstraZeneca really is on to something here. Considering the global market we look at the difficulties China-based developers are having in getting anything approved in the US, as well as considering if and how big pharma can start to make better use of academia-led studies. Finally, we discuss subcutaneous formulations as big pharma tries to maintain revenues in the face of looming patent expiries. We cover a lot in 30 minutes and it's a great way to catch up on the latest news in this market while you're on the move. You can find the recording below, and if you'd like to read the full report you can still [download it for free](#).

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](#)

Evaluate Americas
[+1-617-573-9450](#)

Evaluate APAC
[+81-\(0\)80-1164-4754](#)

© Copyright 2023 Evaluate Ltd.